Omada Health, Inc. (OMDA) Stock Forecast & Price Target

Q: What is OMDA’s average 12-month price target, according to analysts?

Based on analyst ratings, Omada Health, Inc.’s 12-month average price target is 26.33.

Q: What is OMDA’s upside potential, based on the analysts’ average price target?

Omada Health, Inc. has 99.77% upside potential, based on the analysts’ average price target.

Q: Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

Q: How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Q: Is OMDA a Buy, Sell or Hold?

Omada Health, Inc. has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

Q: What is Omada Health, Inc.’s price target?

The average price target for Omada Health, Inc. is 26.33. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $32.00 ,the lowest forecast is $17.00. The average price target represents 99.77% Increase from the current price of $13.18.

Q: What do analysts say about Omada Health, Inc.?

Omada Health, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

Q: How can I buy shares of OMDA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Compare

158 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

OMDA Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Omada

Health, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

OMDA Stock 12 Month Forecast

Average Price Target

$26.33

▲(99.77% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Omada Health, Inc. in the last 3 months. The average price target is $26.33 with a high forecast of $32.00 and a low forecast of $17.00. The average price target represents a 99.77% change from the last price of $13.18.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","18":"$18","23":"$23","28":"$28","33":"$33"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,18,23,28,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.86,16.178461538461537,17.496923076923075,18.815384615384616,20.133846153846154,21.45230769230769,22.770769230769233,24.08923076923077,25.407692307692308,26.726153846153846,28.044615384615383,29.363076923076925,30.681538461538462,{"y":32,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.86,15.742307692307692,16.624615384615385,17.506923076923076,18.389230769230767,19.271538461538462,20.153846153846153,21.036153846153844,21.918461538461536,22.80076923076923,23.68307692307692,24.565384615384616,25.447692307692307,{"y":26.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.86,15.024615384615384,15.189230769230768,15.353846153846153,15.518461538461539,15.683076923076923,15.847692307692308,16.012307692307694,16.176923076923078,16.341538461538462,16.506153846153847,16.67076923076923,16.835384615384616,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.6,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":22.6,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":22.6,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":22.6,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":22.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.38,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.77,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.42,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.73,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.78,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.86,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$32.00

Average Price Target$26.33

Lowest Price Target$17.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ryan MacDonald

Needham

$28

Buy

112.44%

Upside

Reiterated

01/22/26

Omada Health: Strong 2025 Finish, GLP-1 Tailwinds, and Attractive 2026 Valuation Upside Support Reiterated Buy Rating

David Roman

Goldman Sachs

$29→$26

Buy

97.27%

Upside

Reiterated

01/16/26

Omada Health price target lowered to $26 from $29 at Goldman SachsOmada Health price target lowered to $26 from $29 at Goldman Sachs

Elizabeth Anderson CFA

Evercore ISI

$28→$25

Buy

89.68%

Upside

Reiterated

01/15/26

Analysts Offer Insights on Healthcare Companies: Aveanna Healthcare Holdings (NASDAQ: AVAH), Omada Health, Inc. (NASDAQ: OMDA) and United Therapeutics (NASDAQ: UTHR)

Saket Kalia

Barclays

$22

Buy

66.92%

Upside

Reiterated

01/13/26

Barclays Keeps Their Buy Rating on Omada Health, Inc. (OMDA)

Craig Hettenbach

Morgan Stanley

$32

Buy

142.79%

Upside

Reiterated

01/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Omada Health, Inc. (NASDAQ: OMDA), Alkermes (NASDAQ: ALKS) and Apellis Pharmaceuticals (NASDAQ: APLS)

Stan Berenshteyn

Wells Fargo

$17

Hold

28.98%

Upside

Reiterated

01/13/26

Omada Health, Inc. (OMDA) Gets a Hold from Wells Fargo

Richard Close

Canaccord Genuity

$28

Buy

112.44%

Upside

Reiterated

01/12/26

Omada Health: Accelerating Membership and Revenue Growth Underpins Buy Rating and Upside Potential

Destiny Jackson

J.P. Morgan

$31→$32

Buy

142.79%

Upside

Reiterated

11/12/25

Omada Health, Inc. (OMDA) Receives a Buy from J.P. Morgan

Sean Dodge

BMO Capital

$27

Buy

104.86%

Upside

Initiated

11/12/25

Omada Health Positioned for Growth with Strong Financial Performance and Strategic Market Opportunities

Vikram Kesavabhotla

Robert W. Baird

$24

Hold

82.09%

Upside

Initiated

09/04/25

Omada Health initiated with a Neutral at BairdOmada Health initiated with a Neutral at Baird

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ryan MacDonald

Needham

$28

Buy

112.44%

Upside

Reiterated

01/22/26

Omada Health: Strong 2025 Finish, GLP-1 Tailwinds, and Attractive 2026 Valuation Upside Support Reiterated Buy Rating

David Roman

Goldman Sachs

$29→$26

Buy

97.27%

Upside

Reiterated

01/16/26

Omada Health price target lowered to $26 from $29 at Goldman SachsOmada Health price target lowered to $26 from $29 at Goldman Sachs

Elizabeth Anderson CFA

Evercore ISI

$28→$25

Buy

89.68%

Upside

Reiterated

01/15/26

Analysts Offer Insights on Healthcare Companies: Aveanna Healthcare Holdings (NASDAQ: AVAH), Omada Health, Inc. (NASDAQ: OMDA) and United Therapeutics (NASDAQ: UTHR)

Saket Kalia

Barclays

$22

Buy

66.92%

Upside

Reiterated

01/13/26

Barclays Keeps Their Buy Rating on Omada Health, Inc. (OMDA)

Craig Hettenbach

Morgan Stanley

$32

Buy

142.79%

Upside

Reiterated

01/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Omada Health, Inc. (NASDAQ: OMDA), Alkermes (NASDAQ: ALKS) and Apellis Pharmaceuticals (NASDAQ: APLS)

Stan Berenshteyn

Wells Fargo

$17

Hold

28.98%

Upside

Reiterated

01/13/26

Omada Health, Inc. (OMDA) Gets a Hold from Wells Fargo

Richard Close

Canaccord Genuity

$28

Buy

112.44%

Upside

Reiterated

01/12/26

Omada Health: Accelerating Membership and Revenue Growth Underpins Buy Rating and Upside Potential

Destiny Jackson

J.P. Morgan

$31→$32

Buy

142.79%

Upside

Reiterated

11/12/25

Omada Health, Inc. (OMDA) Receives a Buy from J.P. Morgan

Sean Dodge

BMO Capital

$27

Buy

104.86%

Upside

Initiated

11/12/25

Omada Health Positioned for Growth with Strong Financial Performance and Strategic Market Opportunities

Vikram Kesavabhotla

Robert W. Baird

$24

Hold

82.09%

Upside

Initiated

09/04/25

Omada Health initiated with a Neutral at BairdOmada Health initiated with a Neutral at Baird

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Omada Health, Inc.

3 Months

xxx

Success Rate

3/5 ratings generated profit

Average Return

-3.80%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of -3.80% per trade.

1 Year

Saket KaliaBarclays

Success Rate

1/5 ratings generated profit

Average Return

-15.06%

a rating ―

Copying Saket Kalia's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -15.06% per trade.

2 Years

xxx

Success Rate

1/5 ratings generated profit

Average Return

-15.06%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 20.00% of your transactions generating a profit, with an average return of -15.06% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OMDA Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, OMDA has received 9 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. OMDA average Analyst price target in the past 3 months is 26.33.

Each month's total comprises the sum of three months' worth of ratings.

OMDA Financial Forecast

OMDA Earnings Forecast

Next quarter’s earnings estimate for OMDA is <$0.01 with a range of -$0.07 to $0.06. The previous quarter’s EPS was -$0.06. OMDA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year OMDA has Performed in-line its overall industry.

OMDA Sales Forecast

Next quarter’s sales forecast for OMDA is $69.73M with a range of $68.60M to $74.90M. The previous quarter’s sales results were $68.03M. OMDA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year OMDA has Performed in-line its overall industry.

OMDA Stock Forecast FAQ

What is OMDA’s average 12-month price target, according to analysts?

Based on analyst ratings, Omada Health, Inc.’s 12-month average price target is 26.33.

What is OMDA’s upside potential, based on the analysts’ average price target?

Omada Health, Inc. has 99.77% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is OMDA a Buy, Sell or Hold?

Omada Health, Inc. has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is Omada Health, Inc.’s price target?

The average price target for Omada Health, Inc. is 26.33. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $32.00 ,the lowest forecast is $17.00. The average price target represents 99.77% Increase from the current price of $13.18.

What do analysts say about Omada Health, Inc.?

Omada Health, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of OMDA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Omada Health, Inc. (OMDA) Stock Forecast & Price Target

OMDA Analyst Ratings

OMDA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Omada Health, Inc.

OMDA Analyst Recommendation Trends

OMDA Financial Forecast

OMDA Earnings Forecast

OMDA Sales Forecast

OMDA Stock Forecast FAQ

Detailed List of Analyst Forecasts